COVID-19 represents an unprecedented health, social and economic challenge in Australia and around the world. Support Burnet’s COVID-19 emergency response today.
INTRODUCTION: Ex-prisoners with a history of injecting drug use (IDU) experience disproportionate drug-related harm. Rapid resumption of substance use following prison release is common and evidenced in high rates of overdose mortality. However, few studies have documented the rate of IDU resumption following prison release or identified risk factors for relapse.
METHODS: Structured interviews were conducted with 533 adults with a history of IDU in Queensland, Australia prior to release from prison and approximately 1, 3 and 6 months post-release. Incidence of self-reported IDU resumption was calculated overall and for each follow-up interval. Risk factors associated with time to resumption of IDU were estimated using discrete-time survival analysis.
RESULTS: IDU resumption was reported by 41% of participants during a median of 98days of follow-up (IQR=94-121), an overall crude incidence of 1.06 per person-year. The highest rate was observed in the first month (23%; crude incidence 2.24 per person-year). In adjusted discrete-time survival analyses, being unemployed at the previous interview (AHR=1.59; 95%CI:1.10-2.30), shorter incarceration (</=90days vs. >365days; AHR=2.20; 95%CI:1.33-3.65), and IDU during the index incarceration (AHR=2.80; 95%CI:1.92-4.09) were significantly associated with time to IDU resumption; parole was protective (AHR=0.66; 95%CI:0.47-0.92).
CONCLUSIONS: Evidence-based efforts to prevent IDU in prison and IDU resumption after release are important for both prisoner and public health. Enhancing opportunities for employment and capitalising on the short-term benefits of parole for ex-prisoners may delay resumption of IDU after release from prison. These strategies should complement rather than replace harm reduction efforts for this high-risk population.
This work was supported by Australian National Health and Medical Research Council (NHMRC) Strategic Award #409966 and the Centre for Research Excellence on Injecting Drug Use (CREIDU) #1001144. RW is supported by NHMRC Postgraduate Scholarship #603756 and CREIDU. JY is supported by a Melbourne University International Research Scholarship, MS is supported by NHMRC Career Development Fellowship #1090445, PA is supported by CREIDU, MH is supported by NHMRC Principal Research Fellowship #1112297, SK is supported by NHMRC Senior Research Fellowship #1078168. The funding sources had no role in the study design, collection or analysis of data, or in the writing or submission of the manuscript. The authors acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Programme.